T-cell-based Immunotherapy: Adoptive Cell Transfer and Checkpoint Inhibition

Roch Houot (1, 2) , Liora Michal Schultz (3) , Aurelien Marabelle (4) , Holbrook Kohrt (5)

1 MiCa - Microenvironnement et cancer
2 Service d'hématologie clinique
3 Stanford University
4 IGR - Institut Gustave Roussy
5 Department of Medicine

Tumor immunotherapy has had demonstrable efficacy in patients with cancer. The most promising results have been with T-cell-based therapies. These include adoptive cell transfer of tumor-infiltrating lymphocytes, genetically engineered T cells, and immune checkpoint inhibitor antibodies. In this review, we describe the different T-cell-based strategies currently in clinical trials and put their applications, present and future, into perspective. Cancer Immunol Res; 3(10); 1115-22. ©2015 AACR

Domains: Life Sciences [q-bio]

Roch Houot, Liora Michal Schultz, Aurelien Marabelle, Holbrook Kohrt. T-cell-based Immunotherapy: Adoptive Cell Transfer and Checkpoint Inhibition. Cancer Immunology Research, 2015, 3 (10), pp.1115--1122. ⟨10.1158/2326-6066.CIR-15-0190⟩. ⟨hal-01216199⟩